Aeromics

Aeromics is the 1st clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke.

Aeromics Inc. is a preclinical company developing the world’s 1st clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. A paradigm shift in our understanding of water physiology was the discovery aquaporins, proteins that form water channels to allow water into and out of cells, by Peter Agre (2003 Nobel Prize in Chemistry). Despite the vital role of aquaporins in maintaining water homeostasis and its implications in various disease states, therapeutic agents targeting aquaporins have until now remained elusive. Aeromics’ drug candidate, AER-271, targets aquaporin-4 (AQP4), the primary water channel in the brain, and has best-in-class credentials for acute intravenous therapy for stroke-related cerebral edema (CE).